Drug intelligence / Profile preview

Mai'an Granules

Development stage: Unknown
Lead developer: Shanghai Kaibao Pharmaceutical
Administration: Oral

Overview

Mai'an Granules (脉安颗粒) is a traditional Chinese medicine (TCM) product developed and marketed by Shanghai Kaibao Xinyi. It is formulated from extracts of *Crataegus pinnatifida* (Hawthorn) and *Pueraria lobata* (Kudzu root). The drug is primarily indicated for the treatment of hyperlipidemia and the prevention of atherosclerosis. It functions by lowering blood lipid levels and improving vascular elasticity, thereby facilitating better blood circulation and reducing the risk of cardiovascular events. As a commercialized product in China, it is available in an oral granule formulation.

Brand names: Mai'an Granules脉安颗粒
Other names: Mai'an脉安

Beyond the preview

Go deeper on Mai'an Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mai'an Granules.

Explore the full profile